Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Natilizumab will become an important option for newly diagnosed MS patients starting treatment, or for patients currently on interferon beta-1a or glatiramer acetate with refractory breakthrough disease.

Natalizumab Receives Accelerated FDA Approval For MS